Navigation Links
Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
Date:7/1/2011

SOUTH PLAINFIELD, N.J., July 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal. The published three-month data showed that treatment with ataluren resulted in statistically significant improvements in chloride channel activity, CF-related cough and positive trends in lung function.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

"These encouraging data demonstrating statistically significant pharmacodynamic activity support the potential of ataluren for a significant subset of severely affected CF patients," stated Professor Michael Wilschanski, Director, Pediatric Gastroenterology, Hadassah University Hospital. "The results are important because they suggest that ataluren promotes the production of full-length, functional cystic fibrosis transmembrane conductance regulator (CFTR) protein and addresses the underlying cause of the disorder. Currently available treatments for cystic fibrosis only address symptoms, and new therapies such as ataluren are urgently needed."

Patients with CF lack adequate levels of the CFTR protein, a chloride channel necessary for the normal function of the lungs, pancreas, liver and other organs. In nmCF, an interruption in the genetic code—known as a nonsense mutation—prematurely halts the synthesis of CFTR, causing the protein to be short and non-functioning. Nonsense mutations are categorized as Class I mutations that result in little or no production of the CFTR protein. CF patients with Class I mutations typically experience more severe disease symptoms than those with lower-risk genotypes, including a greater than twofold increased risk of death(1), a higher probability of end-stage lung disease(2), and a higher prevalence of pancreatic insufficiency.(2) It is estimated that nonsense
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
2. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
3. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
4. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
5. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
6. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
7. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
8. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
9. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... Dec 12, 2014 Mindray Medical International Limited ... manufacturer and marketer of medical devices worldwide, today announced ... shareholders held in Hong Kong ... Mindray shareholders voted to re-elect incumbent directors Li Xiting ... Mindray,s shareholders did not re-elect Peter Wan ...
(Date:12/13/2014)... INDIANAPOLIS , Dec. 12, 2014  Novo ... Racing Teams (CGRT), today announced a multi-year extension of their ... of the No. 83 Novo Nordisk Chip Ganassi Racing entry, ... Series. Kimball, 29, from Camarillo, ... with diabetes in the history of INDYCAR to win a ...
(Date:12/13/2014)... DUBLIN , Dec. 11, 2014 Research ... announced the addition of the "China Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... of chemical drug preparation and active pharmaceutical ingredient ... preparation industry is generally higher than that of ...
Breaking Medicine Technology:Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7China Chemical Pharmaceutical Industry Report, 2013-2016 2China Chemical Pharmaceutical Industry Report, 2013-2016 3
... PRINCETON, N.J. , June 14 Covance Inc. (NYSE: ... Company,s 30th Annual Growth Stock Conference on Wednesday, June 16, 2010 ... the presentation at www.covance.com .  In order to register and download any ... , , ...
... June 14 MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ... Cheshire, England to manage its planned Phase IIb clinical trial ... candidate for treatment of primary multiple sclerosis-related fatigue (PMSF). , ... In an earlier Phase IIa study, MCT-125 ...
Cached Medicine Technology:MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 2MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 3MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... to lose weight might consider heading to the cardio ... out this month. // ,Both those who ... of weight, according to findings from an NIH-funded study ... while exercisers maintained their strength and muscle mass and ...
... produced a vaccine that activates the immune systems in ... ,During a clinical trial of 67 patients, researchers ... vaccines were injected pre and post surgery of the ... nearly 70 percent of patients. The November 15 issue ...
... drinks works as well as some sports drinks like Gatorade. ... and conducted by Indiana University // suggested found that ... 50% longer than those drinking a carbohydrate drink, an effect ... ,The story was picked up as mainstream news in ...
... memory during and after menopause, a change thought to be ... during that time. // ,Now, research from the ... help women retain certain memory functions. In a study in ... Metabolism, they report that a group of postmenopausal women showed ...
... hearing damage from acoustic shock, say health experts. // , ... functioning of the ear or of the nervous system, which ... earphone by a sudden sharp rise in the acoustic pressure ... a bleep or any unexpected noise. Two thirds of call ...
... identified by scientists from the Wistar Institute in Philadelphia and ... repression of the p53 protein // which is the most ... ,The new molecular pathway described in the study suggests ... many types of cancer. A report on the team's findings ...
Cached Medicine News:Health News:New Study Weighs Benefits of Exercise, Diets 2Health News:A novel vaccine proves a shot in the arm for colorectal cancer patients 2Health News:Hormone Therapy May Improve the Trip Down Memory Lane 2Health News:Regulatory Mechanism for Tumor Suppressor Protein Identified 2Health News:Regulatory Mechanism for Tumor Suppressor Protein Identified 3
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... Chrome plated brass. The Laryngoscope handle that ... secret is the o-rings which create a ... you to keep the batteries in when ... a high quality standard/conventional chrome-plated brass handle ...
... with blade. Rusch offers a reliable tradition ... The designs of these blades have been ... the world over to minimize maintenance requirements. ... the finest surgical grade stainless steel to ...
... laryngoscope blades are designed with the clinician ... bundle can be removed to simplify cleaning ... areas. Our unique snap-on mechanism eliminates screws ... blades are interchangeable with other green coded ...
Medicine Products: